RxDoctor Payments Data

Tatsiana Halkova, MD

Family Medicine · Eau Claire, WINPI 1821113242

Payments from drug & device makers

$823in general payments, 2019–2025

Across 12 payments — averaging $68.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$210
  • Lundbeck LLC$151
  • GSK$140
  • Phathom Pharmaceuticals, Inc.$125
  • Novo Nordisk$116
  • Pfizer$52
  • plus $28 from 1 others

What the payments were for

  • Food & beverage$823100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$823 in reported general payments places this provider in the 85th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$81,573
Medicare patients
260
Services billed
828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$82,050
OzempicSemaglutide56$59,289
JardianceEmpagliflozin43$51,803
VascepaIcosapent Ethyl68$31,221
LinzessLinaclotide36$29,136
JanuviaSitagliptin Phosphate28$29,025
RybelsusSemaglutide20$25,988
MounjaroTirzepatide23$21,778
XareltoRivaroxaban13$21,095
Spiriva RespimatTiotropium Bromide25$17,917
TradjentaLinagliptin21$17,670
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$17,518
TrulicityDulaglutide17$15,701
Advair HfaFluticasone Propion/Salmeterol32$14,904
NexletolBempedoic Acid14$12,321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$116$85,27776 claims
PfizerEliquis$52$82,05076 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$140$37,07267 claims
Johnson & JohnsonXarelto$28$21,09513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in Eau Claire

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →